Статья
КОМБИНАЦИЯ ИНГИБИТОРА АПФ С АГОНИСТОМ I1 -ИМИДАЗОЛИНОВЫХ РЕЦЕПТОРОВ: НОВЫЕ ВОЗМОЖНОСТИ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ
Количество больных с метаболическим синдромом и ожирением прогрессивно увеличивается. Особенностями артериальной гипертензии при ожирении являются активация ренин-ангиотензин-альдостериновой системы и симпато-адреналовой системы (САС), наличие воспаления, раннее и выраженное поражение органов-мишеней, что необходимо учитывать при выборе рациональной антигипертензивной терапии. Помимо этого, комбинированная антигипертензивная терапия должна позитивно влиять на вес пациента, улучшать чувствительность тканей к инсулину, метаболический профиль (углеводный и липидный обмен). Одним из путей решения поставленных задач является назначение комбинации периндоприла и моксонидина, которая обладает синергетическим эффектом в отношении достижения целевого уровня артериального давления, органопротекции, подавления гиперактивации САС и инсулинорезистентности.
1. Leonova MV, Shteinberg LL, Belousov YB, et al. Pharmacoepidemiology of arterial hypertension in Russia: the analysis of physicians acceptance (according to the results of PIFAGOR IV). Systemic Hypertension. 2015; 12 (1): 19-25. Russian (Леонова М. В., Штейнберг Л. Л., Белоусов Ю. Б. и др. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015; 12 (1): 19-25).
2. Mancia G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Blood pressure 2013; 22 (4): 193-278.
3. Muromceva GA, Koncevaya AV, Konstantinov VV, et al. The prevalence of risk factors for non-infectious diseases in the Russian population in 2012-2013. Results of the ESSAY-RF study Cardiovascular Therapy and Prevention 2014; 6: 4-11. Russian (Муромцева Г. А., Концевая А. В., Константинов В. В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ Кардиоваскулярная терапия и профилактика 2014; 6: 4-11).
4. Nedogoda SV. Obesity and arterial hypertension: theory and practice of optimal antihypertensive drug choosing. Moscow: Medikom, 2012. p26. Russian (Недогода С. В. Ожирение и артериальная гипертензия: теория и практика выбора оптимального гипотензивного препарата. Москва: Медиком, 2012. 26c.).
5. Frei M. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S25-S28.
6. Kuppers HE, Jager BA, Luszick JH, et al. Placebo-controlled comparison of efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-7.
7. Prichard BN, Jager BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002; 11: 166-72.
8. Karpov IuA, Shal’nova SA, Deev AD. Prestarium in patients with arterial hypertension and ischemic heart disease (or risk factors) — safe achievement of target blood pressure level (the PREMIERA study). Kardiologiia. 2006; 46: 21-27 (Карпов Ю.А., Шальнова С. А., Деев А. Д. от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) — безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы Кардиология 2006; 6: 32-8).
9. Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther. 2004; 11: 199-205.
10. Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens. 2004; 6: 10-7.
11. Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906.
12. Beckett NS, et al. Treatment of Hypertension in Patients 80 Years of Age or OlderN Engl J Med. 2008; 358.
13. ADVANCE collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.
14. Koz C, Baysan O, Yokusoglu M, et al. The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Med Sci Monit 2009; 15 (7): PI 41-5.
15. Nedogoda SV, et al. Randomized Trial of Perindopril, Enalapril, Losartan And Telmisartan in Overweight or Obese Patients With Hypertension. Clin Drug Investig 2013, 33: 553-61.
16. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl. 1999; 17 (3): S29-35.
17. Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. J Clin Pract Suppl. 2004; (139): 26-32. 1
18. Jacob S, Klimm HJ, Rett K, et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2004; 112 (6): 315-22. 1
19. Haczynski J, Flasinski J, Przewlocka-Kosmala M Effect of moxonidine on left ventricular hypertrophy in hypertensive patients Journal of Clinical and Basic Cardiology 2001; 4 (1): 61-5.
20. Vonend O, Marsalek P, Russ H et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-17.
21. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006; 48: 80-6.
22. Antony I, Lerebours G, Nitenberg A, et al. Angiotensin-Converting Enzyme Inhibition Restores Flow-Dependent and Cold Pressor Test–Induced Dilations in Coronary Arteries of Hypertensive Patients Circulation. 1996; 94: 3115-22.
23. Bots ML, Remme WJ, Lüscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA Trial. Cardiovasc Drugs Ther. 2007; 21: 269-79.
24. Ferrari A. PERTINENT-PERindopril-Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial: A sub-study of the EUROPA Study. Cardiovasc Drugs Ther. 2003; 17: 83-91
25. Nedogoda S, Ledyaeva A, Chumachok E, et al. Randomized Trial of Perindopril, Enalapril, Losartan And Telmisartan in Overweight or Obese Patients With Hypertension. Clin Drug Investig 2013; 33: 553-61. 2
26. Sharma AM, Pischon T, Engeli S, et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001; 19: 667-74.
27. Mychka VB, Chazova IE. Perindopril in treatment for mild arterial hypertension and metabolic syndrome. Arterial hypertension 2002; 8: 36-41. (Мычка В. Б., Чазова И. Е. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия 2002; 8: 36-41).
28. Chazova IE, Almazov VA, Shlyakhto EV. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, Obesity and Metabolism 2006; 8: 456-65.
29. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004 Sep; 18 (9): 669-75.
30. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin. 2004 Mar; 20 (3): 359-67.
31. Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. International Journal of Hypertension. 2013; 2013: 1-9.
32. Jandrain B, Herbaut C, Depoorter J. Long-term acceptability of perindoprol in type II diabetic patients with hypertension. Am J Med 1992; 92: 91s-94s.
33. Andrejak M., Santoni JP, Carre A, et al. A double-blind comparison of perindopril and HCTZ-amiloride in mild to moderate essential hypertension. Fundam Clin Pharmacol 1991; 5: 185-92.
34. Krysiak R. The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Pol J Endocrinol 2010; 61 (3): 280-6.
35. Krysiak R, Sierant M, et al. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Pol J Endocrinol 2010; 61 (6): 683-90.
36. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17 (Suppl 3): S29-S35.
37. Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovasc. Pharmacol. 1998; 32: 616-20.
38. Remková A, Kratochvíl'ová H, Ďurina J. Impact of the therapy by renin–angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension Journal of Human Hypertension. 2008; 22, 338-45.
39. Karlafti EF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection Journal of pharmacy & bioallied sciences 2013; 4: 253.
40. Wenzel RR, Spieker L, Qui S, et al. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension. 1998; 32: 1022-7.
41. The guidelines of the experts of the Russian scientific society of cardiology for the diagnosis and treatment of metabolic syndrome, the second revision. Practical medicine 2010; 5 (44): 81-101. Russian (Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома, второй пересмотр Практическая медицина 2010; 5 (44): 81-101).
42. Chen JM, Heran BS, Wright JM, et al. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst Rev 2009; 4.